• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

    3/15/23 4:05:26 PM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DICE alert in real time by email
    • IND application for DICE's lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023
    • First participants dosed in Phase 1 clinical trial of second oral IL-17 antagonist DC-853; topline data in healthy volunteers expected in 2H 2023
    • Ended 2022 with $574.2 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones

    SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate achievements.

    "We have entered 2023 with strong momentum and continue to make excellent progress advancing our oral IL-17 programs, including our lead product candidate DC-806 and fast follower DC-853," said Kevin Judice, Ph.D., CEO of DICE Therapeutics. "Following the recent U.S. Food and Drug Administration (FDA) clearance of our investigational new drug (IND) application for DC-806, we remain on track to initiate a global Phase 2b clinical trial in the first half of 2023. In addition, we began dosing healthy volunteers in our Phase 1 trial with DC-853 and expect topline data in the second half of 2023. We are also continuing to utilize our DELSCAPE platform to advance our earlier stage research and development (R&D) programs, expanding our pipeline to other validated targets in immunology."

    Recent Highlights

    • An IND application has been cleared by the FDA and is in effect for DICE's lead oral IL-17 antagonist, DC-806.

      • Following positive Phase 1 proof-of-concept data announced in October 2022, DICE plans to initiate a global, dose-ranging Phase 2b clinical trial in patients with moderate-to-severe psoriasis in the first half of 2023 to further explore peak efficacy with a longer duration of treatment.

    • Results from DICE's Phase 1 proof-of-concept clinical trial of DC-806, including additional biomarker data, will be presented in a late-breaking oral session at the 2023 American Academy of Dermatology (AAD) Annual Meeting on Saturday, March 18, 2023.

    • DICE has initiated a Phase 1 clinical trial of its second oral IL-17 antagonist, DC-853, in healthy volunteers following the recent acceptance of a clinical trials authorization application by the United Kingdom's Medicines and Healthcare products Regulatory Agency.

      • Topline data from the Phase 1 clinical trial of DC-853 in healthy volunteers is expected in the second half of 2023.

    • DICE continues to advance its earlier-stage R&D pipeline and intends to nominate an oral development candidate targeting α4β7 for the treatment of inflammatory bowel disease in 2023.

    Fourth Quarter and Full Year 2022 Financial Highlights

    • Cash Position: Cash, cash equivalents and marketable securities totaled $574.2 million at December 31, 2022. The Company expects its current cash position to fund operations through expected key clinical milestones and into 2026.

    • R&D Expenses: Research and development expenses were $20.1 million and $62.6 million for the fourth quarter and full year ended December 31, 2022, respectively, as compared to $12.2 million and $36.5 million for the same periods in 2021. The increase was primarily due to the advancement of DICE's IL-17 franchise and other research programs, and increases related to personnel expenses due to an increase in headcount and stock-based compensation expense.

    • G&A Expenses: General and administrative expenses were $6.4 million and $25.7 million for the fourth quarter and full year ended December 31, 2022, respectively, as compared to $4.0 million and $12.2 million for the same periods in 2021. The increase was primarily due to an increase in personnel costs related to increased headcount and stock-based compensation and an increase in professional service fees and other costs associated with operating as a publicly-traded company.

    • Net Loss: Net loss totaled $23.2 million for the fourth quarter of 2022 with non-cash stock compensation expense of $3.3 million, compared to $16.2 million for the fourth quarter of 2021 with non-cash stock compensation expense of $1.7 million. Net loss was $83.9 million for the full year ended December 31, 2022, with non-cash stock compensation expense of $12.8 million, compared to $49.0 million for the full year ended December 31, 2021, with non-cash stock compensation expense of $5.6 million.

    About the DICE Oral IL-17 Franchise

    DICE is developing orally-available, small molecule antagonists of the pro-inflammatory signaling molecule IL-17, an immune cell-derived cytokine. Blockade of this pathway has proven to be an effective therapy in a number of auto-immune diseases. The anti-IL-17 injectable biologics have been approved for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

    The DICE oral IL-17 franchise includes the lead therapeutic candidate, DC-806, the differentiated fast-follower candidate, DC-853, and the novel scaffold program. DICE is developing its lead therapeutic candidate, DC-806, for the treatment of psoriasis and plans to expand development to additional indications in which the marketed anti-IL-17 injectable biologics have proven to be effective.

    About DICE Therapeutics, Inc.

    DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company's DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE's lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting the integrin α4ß7 for the treatment of inflammatory bowel disease.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the Company's future plans and prospects, the Company's anticipated runway, any expectations regarding the safety or efficacy of DC-806 and other candidates under development, the ability of DC-806 to treat psoriasis or related indications, the planned timing of the Company's clinical trials, data results and further development of DC-806 and DC-853, and expectations regarding an oral development candidate targeting α4β7. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of factors, including risks and uncertainties related to the Company's ability to advance DC-806, DC-853 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the Company's therapeutic candidates, the timing and results of preclinical and clinical trials, the Company's ability to fund development activities and achieve development goals, the impact of the COVID-19 pandemic on the Company's business, its ability to protect its intellectual property and other risks and uncertainties described under the heading "Risk Factors" in the Company's annual report on Form 10-K filed on March 15, 2023, and its other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

    DICE THERAPEUTICS, INC.

    Condensed Consolidated Statements of Operations

    (unaudited)

    (In thousands, except share and per share amounts)

      Three Months Ended

    December 31,
      Year Ended

    December 31,
     
      2022  2021  2022  2021 
    Revenue:            
    Collaboration revenue $—  $—  $—  $1,125 
    Operating expenses:            
    Research and development  20,089   12,214   62,559   36,506 
    General and administrative  6,361   3,996   25,662   12,222 
    Total operating expenses  26,450   16,210   88,221   48,728 
    Loss from operations  (26,450)  (16,210)  (88,221)  (47,603)
    Other income (expense):            
    Interest and other income, net  3,697   75   5,213   136 
    Interest and other expense  (471)  (60)  (679)  (174)
    Loss on extinguishment of debt  —   —   (200)  — 
    Change in fair value of warrant liability  —   —   —   (1,318)
    Net loss $(23,224) $(16,195) $(83,887) $(48,959)
    Net loss per share, basic and diluted $(0.51) $(0.44) $(2.13) $(3.95)
    Weighted-average shares used in computing net loss per share, basic and diluted  45,431,180   37,157,057   39,401,106   12,384,015 
                     



    DICE THERAPEUTICS, INC.

    Selected Consolidated Balance Sheet Data

    (unaudited)

    (In thousands)

      December 31, 
      2022  2021 
    Cash, cash equivalents, and marketable securities $574,225  $319,321 
    Total assets  593,978   325,754 
    Total liabilities  26,990   12,805 
    Accumulated deficit  (187,594)  (103,707)
    Total stockholders' equity  566,988   312,949 

    Contacts:

    Media:

    Katie Engleman, 1AB

    [email protected]

    Investors:

    [email protected]

     



    Primary Logo

    Get the next $DICE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DICE

    DatePrice TargetRatingAnalyst
    5/24/2023$38.00Equal Weight
    Wells Fargo
    5/22/2023$71.00Buy
    Canaccord Genuity
    3/31/2023$56.00Buy
    Needham
    3/1/2023Outperform
    TD Cowen
    3/1/2023Outperform
    Cowen
    11/15/2022$65.00Buy
    Guggenheim
    9/14/2022$36.00Overweight
    Cantor Fitzgerald
    9/7/2022$37.00Buy
    Stifel
    More analyst ratings

    $DICE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Ra Capital Management, L.P.

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 5:00:37 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Tetlow Sharon returned 49,841 shares to the company, closing all direct ownership in the company

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:38:19 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Simson Jake

      4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

      8/9/23 4:36:43 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on DICE Therapeutics with a new price target

      Wells Fargo initiated coverage of DICE Therapeutics with a rating of Equal Weight and set a new price target of $38.00

      5/24/23 7:49:57 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on DICE Therapeutics with a new price target

      Canaccord Genuity initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $71.00

      5/22/23 7:17:25 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on DICE Therapeutics with a new price target

      Needham initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $56.00

      3/31/23 7:20:41 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    SEC Filings

    See more
    • SEC Form 15-12G filed by DICE Therapeutics Inc.

      15-12G - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/21/23 8:00:26 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by DICE Therapeutics Inc.

      EFFECT - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/11/23 12:15:08 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by DICE Therapeutics Inc.

      S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)

      8/9/23 9:47:55 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    Leadership Updates

    Live Leadership Updates

    See more
    • ShouTi Appoints Sharon Tetlow to Board of Directors

      ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company's board of directors. Ms. Tetlow will also serve as chair of the audit committee. "On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board," said Daniel Welch, Chairman of the Board, ShouTi. "Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee. With an outstanding track record of advising biopharmaceutical companies, Sharon's perspectiv

      3/29/22 8:00:00 AM ET
      $CBIO
      $DICE
      $VALN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • DICE Therapeutics Expands Management Team and Board of Directors

      Mary Riley, J.D., appointed as general counselLisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE's board of directors. Concurrently, Stephen Zachary, Ph.D., will be stepping down from the Company's board. "Mary, Lisa and Mittie are e

      3/28/22 4:05:00 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    Financials

    Live finance-specific insights

    See more
    • Lilly Completes Acquisition of DICE Therapeutics

      INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new

      8/9/23 9:02:00 AM ET
      $DICE
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

      Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory p-value of 0.0008 DC-806 was well tolerated with an excellent safety profile across all dose groups in healthy volunteers and psoriasis patients with a robust PK profile and clear pharmacodynamic effects on two distinct biomarkers at both high and low doses of DC-806 Data supports further development of DC-806 as potential best-in-class oral agent for psoriasis; DC-806 is expected to advance into a Phase 2b clinical trial in the first half of 2023 Company to host conference cal

      10/11/22 7:00:00 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lilly Completes Acquisition of DICE Therapeutics

      INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new

      8/9/23 9:02:00 AM ET
      $DICE
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly Announces Extension of Tender Offer to Acquire DICE

      INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ:DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire one minute past 11:59 p.m., Eastern time, on July 28, 2023, has been extended until one minute past 11:59 p.m., Eastern time, on Aug. 8, 2023, unless the tender offer is further extended or earlier terminated. The proposed acquisition is expected to close in the third q

      7/25/23 6:55:00 AM ET
      $DICE
      $LLY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of BG, KDNY, QUOT, and DICE

      NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE:BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock. If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-m

      6/24/23 8:11:00 PM ET
      $BG
      $DICE
      $KDNY
      $QUOT
      Packaged Foods
      Consumer Staples
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DICE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      8/9/23 5:00:12 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13G/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      7/10/23 10:20:11 AM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

      SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

      6/23/23 5:10:56 PM ET
      $DICE
      Biotechnology: Pharmaceutical Preparations
      Health Care